Screening method utilizing thalidomide-targeting factor
US9217743B2 · kind B2 · utility
8Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 18, 2010 |
| Grant date | Dec 22, 2015 |
| Priority date | — |
| Expiry date | Oct 18, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.